Abstract: Disclosed are compounds having the following structure: CDK-L-(X)n, where CDK is a CDK4/6 inhibitor group, L is a linking group, X is a radiolabel or hydrogen, n is 1, 2, 3, 4, or 5, and when there are a plurality of X groups, at least one X is a radiolabel. Also described are methods of making and using the compounds. The compounds may be used in PET imaging to quantify CDK4/6 expression in cancers and to treat cancer patients exhibiting tumors which express CDK4/6.

Abstract: The present technology is directed to compounds useful in the imaging of peripheral neurons.

Abstract: The present disclosure describes methods of use of a composition comprising PARPi-fl to be administered to the oral cavity (e.g., via topical application to surfaces of the oral cavity) followed by imaging of the oral cavity for detection of squamous cell carcinoma of the oral cavity (e.g., in vivo, e.g., in a dental office setting or intraoperatively). The results disclosed herein show that topically applied PARPi-fl and subsequent intraoperative imaging of oral cavities can improve surgical removal of squamous cell carcinoma cells compared to healthy cells.

Abstract: The present disclosure relates to methods and kits for detecting SARS-CoV-2 virus in a patient. For example, a method is disclosed that includes contacting at least a portion of a diluted saliva sample, the diluted saliva sample including a saliva sample from a patient and a saline solution, with a radiolabeled SARS-CoV-2-targeted antibody to form a first solution that includes target bound antibody and unbound antibody; separating at least a portion of the target bound antibody from the unbound antibody in the first solution to form a separated target bound antibody solution; and detecting a radiation level in the separated target bound antibody sample indicating the presence of the target bound antibody in the separated target bound antibody sample.

Abstract: The present technology is directed to fluorophore-containing compounds useful in the imaging of peripheral neurons as well as to proteins useful in the treatment (including management) of pain.

Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.

Abstract: Disclosed are compounds having the following structure: CDK-L-(X)n, where CDK is a CDK4/6 inhibitor group, L is a linking group, X is a radiolabel or hydrogen, n is 1, 2, 3, 4, or 5, and when there are a plurality of X groups, at least one X is a radiolabel. Also described are methods of making and using the compounds. The compounds may be used in PET imaging to quantify CDK4/6 expression in cancers and to treat cancer patients exhibiting tumors which express CDK4/6.

Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.

Abstract: Probe systems and methods are disclosed herein. The methods include directly measuring a distance between a first manipulated assembly and a second manipulated assembly, contacting first and second probes with first and second contact locations, providing a test signal to an electrical structure, and receiving a resultant signal from the electrical structure. The methods further include characterizing at least one of a probe system and the electrical structure based upon the distance. In one embodiment, the probe systems include a measurement device configured to directly measure a distance between a first manipulated assembly and a second manipulated assembly. In another embodiment, the probe systems include a probe head assembly including a platen, a manipulator operatively attached to the platen, a vector network analyzer (VNA) extender operatively attached to the manipulator, and a probe operatively attached to the VNA extender.

Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.

Abstract: The present disclosure describes methods of use of a composition comprising PARPi-fl to be administered to the oral cavity (e.g., via topical application to surfaces of the oral cavity) followed by imaging of the oral cavity for detection of squamous cell carcinoma of the oral cavity (e.g., in vivo, e.g., in a dental office setting or intraoperatively). The results disclosed herein show that topically applied PARPi-fl and subsequent intraoperative imaging of oral cavities can improve surgical removal of squamous cell carcinoma cells compared to healthy cells.

Abstract: Presented herein are methods and compositions for non-invasive imaging of TAMs with discoidal high-density lipoproteins to assess prognosis and therapy outcome. TAMs are increasingly investigated in cancer immunology, and are considered a promising target for better and tailored treatment of malignant growths. Although TAMs also have high diagnostic and prognostic value, TAM imaging still remains largely unexplored. Imaging agents/methods provided herein are of value for non-invasive in vivo evaluation of TAM burden, not only in preclinical but also in clinical settings.

Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.

Abstract: Probe systems and methods are disclosed herein. The methods include directly measuring a distance between a first manipulated assembly and a second manipulated assembly, contacting first and second probes with first and second contact locations, providing a test signal to an electrical structure, and receiving a resultant signal from the electrical structure. The methods further include characterizing at least one of a probe system and the electrical structure based upon the distance. In one embodiment, the probe systems include a measurement device configured to directly measure a distance between a first manipulated assembly and a second manipulated assembly. In another embodiment, the probe systems include a probe head assembly including a platen, a manipulator operatively attached to the platen, a vector network analyzer (VNA) extender operatively attached to the manipulator, and a probe operatively attached to the VNA extender.

Abstract: Disclosed are chemical entities of formula (I) wherein R1, R2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.

Abstract: Probe systems and methods are disclosed herein. The methods include directly measuring a distance between a first manipulated assembly and a second manipulated assembly, contacting first and second probes with first and second contact locations, providing a test signal to an electrical structure, and receiving a resultant signal from the electrical structure. The methods further include characterizing at least one of a probe system and the electrical structure based upon the distance. In one embodiment, the probe systems include a measurement device configured to directly measure a distance between a first manipulated assembly and a second manipulated assembly. In another embodiment, the probe systems include a probe head assembly including a platen, a manipulator operatively attached to the platen, a vector network analyzer (VNA) extender operatively attached to the manipulator, and a probe operatively attached to the VNA extender.

Abstract: The present technology provides compositions and nanoemulsions useful in optoacoustic imaging. A composition of the present technology includes at least one contrast agent covalently linked to a targeting agent; where the at least one contrast agent includes a dark quencher; the targeting agent includes an antibody, an antigen, an antigen-targeting ligand, a receptor ligand, or an adhesion peptide; and the at least one contrast agent and targeting agent are covalently linked by a linker of formula (I) X1-L1-X2 (I) where X1 is an amino, amide, S, or O of the at least one contrast agent; L1 is C1-C12 alkylene, C2-C12 alkenylene, C5-C12 cycloalkylene, or C6-C12 arylene; and X2 is an amino, amide, S, or O of the targeting agent.

Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.

Abstract: A method and a gonioradiometer for the direction-dependent measurement of at least one photometric or radiometric characteristic of an optical radiation source. The emission direction of the photometric or radiometric characteristic is described using a system of planes (A, B, C), the planes of which intersect at an intersection line which passes through the radiation centroid of the radiation source, and using an emission angle (?, ?, ?) which specifies the emission direction (?, ?, ?) within a considered plane. A sensor or the radiation source is fastened to a multi-axis articulated robot. The robot is configured to only swivel about precisely one of its axes during a measuring process, in which measurement values relating to different emission angles (?, ?, ?) within a considered plane of the system of planes (A, B, C) or to different planes at a considered emission angle (?, ?, ?) are detected.

Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.